SCHEMBL6807700

SCHEMBL6807700

O=C(O)CN1c2ccccc2COc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
POLB P06746 2/20 0.50
LMNA P02545 1/20 0.50
HSD17B3 P37058 1/20 0.50
HTT P42858 2/20 0.48
TSHR P16473 2/20 0.48
ALOX12 P18054 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
TP53 P04637 1/20 0.46
CBX7 O95931 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
CDY1; CDY1B Q9Y6F8 1/20 0.46
ALDH1A1 P00352 2/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4970176 0.84 KMT2A (0.68) MEN1KMT2APOLBLMNAHTT
SCHEMBL30808661 0.84 KMT2A (0.68) MEN1KMT2APOLBLMNAHTT
SCHEMBL4968156 0.83 MEN1 (0.49) MEN1KMT2APOLBLMNAHTT
SCHEMBL16432726 0.80 CA12 (0.53) MEN1KMT2APOLBTSHRCYP2C9
SCHEMBL5087842 0.80 MEN1 (0.55) MEN1KMT2AALDH1A1
SCHEMBL15486077 0.80 KDM4E (0.55) MEN1KMT2APOLBCYP2C9CYP2C19
SCHEMBL30144051 0.78 POLB (0.51) KMT2APOLBHSD17B3TSHRCYP2C9
SCHEMBL6806107 0.78 HSD17B3 (0.45) MEN1KMT2APOLBLMNAHSD17B3
SCHEMBL2754100 0.76 MEN1 (0.53) MEN1KMT2APOLBLMNAHTT
SCHEMBL9618341 0.75 CA12 (0.65) MEN1KMT2ALMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1475373-A1 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists Ajinomoto Co., Inc. (JP) 2004-11-10 EP disclosed
EP-1471060-A1 5,11-Dihydrodibenzo[b,e][1,4]-oxazepine derivatives as calcium channel antagonists Ajinomoto Co., Inc. (JP) 2004-10-27 EP disclosed
US-6528504-B2 Compounds such as (R)-5,11-dihydro-5-(1-(4-methoxyphenethyl)-piperidine-2-ylmethyl) -dibenzo(b,e)(1,4) oxazepine are useful for treating or preventing abnormal motor functions of gastrointestinal tracts, e.g., irritable bowel syndrome. AJINOMOTO CO., INC. (JP) 2003-03-04 US disclosed
US-20020099047-A1 Oxazepine derivatives and medicine containing the same AJINOMOTO CO., INC. (JP) 2002-07-25 US disclosed
EP-1142884-A1 OXAZEPINE DERIVATIVES AND DRUGS CONTAINING THE SAME Ajinomoto Co., Inc. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099047-A1 Oxazepine derivatives and medicine containing the same CACNG5, GRIK5, KCNB1 MEN1 4438/4885KMT2A 755/4885POLB 2123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.